Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Other illness

• Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
• Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
• Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease

Other

• Myxoid liposarcoma histology
• Pregnancy

• Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
• No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
• Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
• Sarcoma not originating from bone or abdominal or gynecological viscera
• Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
• WHO performance status 0-2
• American Society of Anaesthesiologist (ASA) score 1-3
• No prior RT for the retroperitoneal liposarcoma
• Prior systemic therapy is allowed
• No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
• Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
• Patient deemed able to comply with study requirements according to investigator evaluation
• Signed, IRB-approved written informed consent